1. DATE ISSUED MM/DD/YYYY 1a. SUPERSE 06/26/2019 except that remain in e	ons previously imposed	DEPARTMENT OF HEALTH AND HUMAN SERVICES						
2. CFDA NO. 93.268 - Immunization Cooperative Agreements		Centers for Disease Control and Prevention CDC Office of Financial Resources						
3. ASSISTANCE TYPE Cooperative Agreement				293	9 Brandywine Roa	ad		
4. GRANT NO. 1 NH23IP922606-01-00 Formerly	5. TYPE OF AWARD Demonstration				tlanta, GA 30341			
4a. FAIN NH23IP922606	5a. ACTION TYPE New	v						
6. PROJECT PERIOD MM/DD/YYYY		MM/DD/YYYY	NOTICE OF AWARD					
From 07/01/2019	Through	06/30/2024		AUTHORIZATION (Legislation/Regulations)				
7. BUDGET PERIOD MM/DD/YYYY From 07/01/2019	Through	<i>MM/DD/YYYY</i> 06/30/2020	S	Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.				
8. TITLE OF PROJECT (OR PROGRAM) CDC-RFA-IP19-1901 Immunization and Vaccine	s for Children							
9a. GRANTEE NAME AND ADDRESS								
HEALTH AND SENIOR SERVICES, MISSOUR 920 Wildwood Dr	DEFARIMENT OF			icia Davis /ildwood Dr				
Jefferson City, MO 65109-5796				E OF MISSOURI				
				son City, MO 65109-5796				
				: 573-526-6643				
10a. GRANTEE AUTHORIZING OFFICIAL				RAL PROJECT OFFICER anan Awwad				
Ms. Tonya Loucks 920 WILDWOOD DR				Clifton Rd NE				
JEFFERSON CITY, MO 65109-5796			Immu	nization Services Division (ISD)				
Phone: 000-000-0000			Atlanta, GA 30329-4018					
			Phone	e: 404.718.4623				
		ALL AMOUNTS ARE S						
11. APPROVED BUDGET (Excludes Direct Assistance I Financial Assistance from the Federal Awarding Ag				COMPUTATION of Federal Financial Assistance	(from item 11m)	5,730,169.00		
II Total project costs including grant funds and all oth		1		bligated Balance From Prior Bu	, ,	0.00		
		1,818,889.00	c. Less Cumulative Prior Award(s) This Budget Period 0.00					
		1,189,415.00	d. AMOUN	F OF FINANCIAL ASSISTANCE	THIS ACTION	5,730,169.00		
				deral Funds Awarded to Date	or Project Period	5,730,169.00		
c. Total Personnel Costs d. Equipment		3,008,304.00 0.00		MENDED FUTURE SUPPORT the availability of funds and satis	factory progress of the	project):		
e. Supplies		192,330.00	YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS		
		164,509.00	a. 2		d. 5			
f. Travel			b. 3		e. 6			
g. Construction		0.00	c. 4		f. 7			
h. Other		261,733.00	15. PROGRAM ALTERNATIVE		WITH ONE OF THE FOLLOW			
i. Contractual	·····	1,462,524.00	a. b.	DEDUCTION ADDITIONAL COSTS MATCHING		b		
j. TOTAL DIRECT COSTS -		5,089,400.00	с. d. е.	OTHER RESEARCH (Add / Deduct Optio OTHER (See REMARKS)	on)			
k. INDIRECT COSTS		640,769.00	-					
I. TOTAL APPROVED BUDGET 5,730,169.00			16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING: a. The grant program legislation b. The grant program legislations.					
m. Federal Share 5,730,169.00			c. d.	This award notice including terms and co Federal administrative requirements, cos				
n. Non-Federal Share 0.00			prevail. Accept	ere are conflicting or otherwise inconsi tance of the grant terms and condition the grant payment system.	stent policies applicable to the s is acknowledged by the gra	he grant, the above order of precedence shall antee when funds are drawn or otherwise		
REMARKS (Other Terms and Conditions Atta	ached - X Yes	5	No)	, , , , , , , , , , , , , , , , , , ,				

GRANTS MANAGEMENT OFFICIAL:

Erica Stewart, Grants Management Officer 2939 Flowers Rd TV-2 Atlanta, GA 30341 Phone: 770-488-2769

17.0BJ CL	LASS 41.51	18a. VENDOR CODE	1	18b. EIN		19. DUNS	878092600	20. CONG.	DIST. 03
F	Y-ACCOUNT NO.	DOCUME	NT NO.	ADMINIST	RATIVE CODE	AMT A	ACTION FIN ASST	APPR	OPRIATION
21. a.	9-93909KZ	b. 19NH23I	P922606 C	D.	IP	d.	\$3,459,529.00	e.	75-X-0951
22. a.	9-9390BKG	b. 19NH23I	P922606 C	D.	IP	d.	\$479,234.00	e. 7	5-75-X-0512-009
23. a.	9-9390BKJ	b. 19NH23I	P922606 C	c.	IP	d.	\$51,103.00	e. 7	5-75-X-0512-009

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED
	06/26/2019

GRANT NO. 1 NH23IP922606-01-00

FY	-ACCOUNT NO.		DOCUMENT NO.		ADMINISTRATIVE CODE		AMT ACTION FIN ASST		APPROPRIATION
24.a.	9-9390BKM	b.	19NH23IP922606	C.	IP	d.	\$769,649.00	e.	75-75-X-0512-009
25.a.	9-939ZRWL	b.	19NH23IP922606	c.	IP	d.	\$252,735.00	e.	75-19-0951
26.a.	9-939ZRYH	b.	19NH23IP922606	c.	IP	d.	\$717,919.00	e.	75-19-0951

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$4,688.00	\$4,688.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$4,688.00	\$4,688.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED
	06/26/2019

GRANT NO. 1 NH23IP922606-01-00

Federal Financial Report Cycle					
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date		
07/01/2019	06/30/2020	Annual	09/28/2020		
07/01/2020	06/30/2021	Annual	09/28/2021		
07/01/2021	06/30/2022	Annual	09/28/2022		
07/01/2022	06/30/2023	Annual	09/28/2023		
07/01/2023	06/30/2024	Annual	09/28/2024		

AWARD ATTACHMENTS

Missouri Department of Health

1 NH23IP922606-01-00

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <u>https://www.cdc.gov/grants/federalregulationspolicies/index.html</u>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19-1901, entitled Immunization and Vaccines for Children, and application dated Apr 05, 2019 as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NOA).

Approved Funding: Funding in the amount of \$5,730,169 is approved for the Year 01 budget period, which is July 1, 2019 through June 30, 2020. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

Funding Type	Amount
Project BB1	\$ 409,862
Core Funding	\$5,320,307

Approved But Unfunded: Travel to the following CDC Sponsored or co-sponsored meetings is approved but not funded at this time: National Immunization Conference (NIC), Immunization Awardee Meetings, Influenza Immunization Summit, and the Public Health Informatics Conference.

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO and below.

- Provide guidance, trainings, tools, and technical assistance to award recipient on program area components.
- Host conference calls for sharing information from CDC and between award recipients.
- Work with award recipients on planning and implementation of required and proposed activities.
- Monitor award recipient vaccine spend plan and replenishment providing regular feedback and working with award recipient to address barriers.

- Analyze and report results of surveys regarding national, state and selected local level vaccination coverage.
- Analyze and report result of surveys of award recipient plans and activities related to preparedness.
- Collaboration with external partners to promote IIS in national health IT settings.
- Develop and support improvements in IIS data quality and program measures to assess IIS performance.
- Use IIS submitted data to develop methods to estimate national vaccination coverage and calculate vaccination coverage estimates for routinely recommended childhood vaccines.
- Use IIS submitted data to monitor seasonal or pandemic influenza vaccination among ages that are available in the IIS data.
- Assist, as needed, in the development of data collection and reporting methods for school-enterer vaccination coverage surveys.
- Provide VFC policy guidance via the VFC Operations Guide, periodic trainings and conference calls, including use of the CDC developed quality assurance site visit tools, to assist award recipient implement their VFC program in accordance with federal requirements.
- Provide subject matter guidance in all program component areas.

Direct Assistance (DA): DA is awarded in the amount of \$4,688 in this budget period.

Summary/Technical Review Response Requirement: The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted in GrantSolutions Grant Notes and approved, in writing, by the Grants Management Specialist/Grants Management Officer (GMS/GMO) noted in the CDC Staff Contacts section of this NOA, no later than 60 days from the budget period start date. Failure to submit the required information by the due date, September 3, 2019, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Budget Revision Requirement: By September 3, 2019 the recipient must submit a revised budget with a narrative justification in GrantSolutions Grant Notes. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

<u>Addition alternative</u>: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

- Recipients may not use funds for research.
- Recipients may not use funds for clinical care except as allowed by law.

- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients.
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- In accordance with the United States Protecting Life in Global Health Assistance policy, all nongovernmental organization (NGO) applicants acknowledge that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. See Additional Requirement (AR) 35 for applicability (<u>https://www.cdc.gov/grants/additionalrequirements/ar-35.html</u>).

Indirect Costs: Indirect costs are approved based on the negotiated indirect cost rate agreement dated March 9, 2018, which calculates indirect costs as follows, a Provisional is approved at a rate of 21.30% of the base, as shown in your agreement. The effective dates of this indirect cost rate are from July 1, 2019 to June 30, 2021.

REPORTING REQUIREMENTS

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132**, "**Performance Progress and Monitoring Report**", **Expiration Date 8/31/2019**. The components of the PPMR are available for download at: <u>https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html</u>.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):

Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity affecting the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially

affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services Freda Johnson, Grants Management Specialist Centers for Disease Control and Prevention Infectious Disease Services Branch 2939 Flowers Road, MS TV2 Atlanta, GA 30341 Fax: 770-488-2640 (Include "Mandatory Grant Disclosures" in subject line) Email: <u>WVE2@CDC.GOV</u> (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services Office of the Inspector General ATTN: Mandatory Grant Disclosures, Intake Coordinator 330 Independence Avenue, SW Cohen Building, Room 5527 Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email: <u>MandatoryGranteeDisclosures@oig.hhs.gov</u>

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to <u>hhstips@oig.hhs.gov</u> or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application. All award funds must be tracked and reported separately.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Subaccount Title: 19NH23IP922606

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:

Freda Johnson, Grants Management Specialist Centers for Disease Control and Prevention Infectious Disease Services Branch 2939 Flowers Road, MS TV2 Atlanta, GA 30341 Telephone: 770-488-3107 Fax: 770-488-2640 Email: Fjohnson5@cdc.gov

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Grants Management Officer: The GMO is the federal official responsible for the business and other nonprogrammatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NOA, including revisions to the NOA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization. GMO contact information is located on Page 1 of this NOA.